<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821987</url>
  </required_header>
  <id_info>
    <org_study_id>PUIH-SAA</org_study_id>
    <nct_id>NCT03821987</nct_id>
  </id_info>
  <brief_title>Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA</brief_title>
  <official_title>Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The haplotype HSCT system including Bu(0.8mg/kg Q6hx2d)CTX(50mg/kgx4d)rATG(2.5mg/kgx4d) ,
      established in Institute of Hematology of Peking University ,has been evaluated to be
      effective for acquired SAA.But some patients with high risk factors may not tolerate CTX
      200mg/kg,alternative conditioning regimen including Bu/Fludarabine/dercreased CTX was studied
      in this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d
      ,CTX(cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.

      BM or Blood samples from patients were obtained to assess engraftment and chimerism after
      HSCT. The time point that investigators monitor BM or blood samples at 1 month,2 months, 3
      months,6 months, 9 months and 1year,2years,3years 5 years after HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX(cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year cumulative incidence overall survival</measure>
    <time_frame>1 year post HSCT</time_frame>
    <description>Tne cumulative incidence of overall survival at 1 year post HSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>one month Transplantation related mortality</measure>
    <time_frame>1 month post HSCT</time_frame>
    <description>Tne cumulative incidence of transplantation related motality at 1 month post HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>1 month post HSCT</time_frame>
    <description>Tne cumulative incidence of engraftment at 1 moths post HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>0ne month regimen-related toxicity</measure>
    <time_frame>1 month post HSCT</time_frame>
    <description>Tne cumulative incidence of regimen related toxicity at 1 month post HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aGVHD</measure>
    <time_frame>100 days post HSCT</time_frame>
    <description>Tne cumulative incidence of acute GVHD at Day 100 post HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure-free survival</measure>
    <time_frame>1 year post HSCT</time_frame>
    <description>The cumulative incidence of failure-free survival at 1year post HSCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Aplastic Anemia</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Engraft Failure</condition>
  <arm_group>
    <arm_group_label>BFCA regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.
BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.</description>
    <arm_group_label>BFCA regimen</arm_group_label>
    <other_name>Busulfan</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A：inclusion criteria

          1. Patients diagnosed as acquired severe aplastic anemia(SAA) /very vSAA

          2. patients with age 3-55 years

          3. patients have no matched sibling donor

          4. Patients have no matched unrelated donor

          5. patients have no severe infection

          6. Patients have no severe organ dysfunction

          7. patients have risk factors of potential intolerance to previous condition regimen
             including BuCy(200mg/kg)and ATG

          8. Consent form signed

        B. Exclusion criteria ：

          1. patients with congenital SAA/vSAA

          2. patients with age&lt; 3years or &gt;55 years

          3. patients with matched sibling donor

          4. patients with matched URD

          5. patients with severe infection

          6. patients with severe organ dysfunction

          7. pregnancy women

          8. no Consent form signed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Universiy Institute of Hematology,People's Hospital Pekiking Universiyy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojun Huang, Prof.</last_name>
    <phone>861088326006</phone>
    <email>lpxu_0415@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lanping Xu</last_name>
    <phone>861088326904</phone>
    <email>lpxu_0415@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Institute of Hematology,People's hospital Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanping Xu, Prof.</last_name>
      <phone>8613641028627</phone>
      <email>lpxu_0415@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanru Ma</last_name>
      <phone>8613641134402</phone>
      <email>lpxu_0415@vip.sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang,MD</investigator_full_name>
    <investigator_title>Director of Institute Hematology,Peking University</investigator_title>
  </responsible_party>
  <keyword>haploidentical transplantation</keyword>
  <keyword>aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

